Hyponatremia May Be Negative Prognostic Parameter for Malignant Mesothelioma

Share this content:

the Cancer Therapy Advisor take:

Hyponatremia may be a negative prognostic parameter in patients with malignant mesothelioma, according to a recent study published in Supportive Care in Cancer.

Italian researchers led by Rossana Berardi, MD, at the Marche Polytechnic University in Ancona looked  at 62 consecutive patients with histologically or cytologically proven advanced malignant pleural mesothelioma. All patients were undergoing first-line pemetrexed-based chemotherapy between January 2003 and September 2013. Second-line chemotherapy was administered to 29 patients.

They found that the onset of hyponatremia during treatment was significantly associated with worsened overall survival. Hyponatremia occurrence during first- and second-line chemotherapy was significantly associated with shorter median progression-free survival.

Furthermore, upon multivariate analysis, they found that only hyponatremia was an independent factor as well as a predictive factor for poorer response to first- and second-line pemetrexed-based chemotherapy treatment.

“To our knowledge, this is the first study to evaluate the association of hyponatremia with the outcome of malignant pleural mesothelioma patients,” the authors concluded.

X-ray showing malignant mesothelioma / Science Source
Hyponatremia may be a negative prognostic parameter in patients with malignant mesothelioma.
The aim of this study was to assess the prognostic role of hyponatraemia in malignant pleural mesothelioma. The results show that hyponatraemia might be considered a negative prognostic parameter in malignant pleural mesothelioma patients.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs